safeTY-engager Platform (Collaborative)
Cancer
Discovery/Pre-clinicalActive
Key Facts
About Yumab
YUMAB is a specialized German contract research organization (CRO) and technology provider focused exclusively on therapeutic antibody discovery and development. Leveraging nearly 30 years of collective expertise and a proprietary, human-derived antibody library platform, the company offers end-to-end services from target identification to lead optimization, including antibody engineering and humanization. As a private, revenue-generating entity, YUMAB serves as a strategic partner for pharma and biotech companies, accelerating and de-risking their antibody drug development programs through flexible contract research agreements.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |